人間のアニオテンシン変換酵素-リシノプリル複合体の結晶構造
Ramanathan Natesh1, Sylva L U Schwager, Edward D Sturrock
1Department of Biology and Biochemistry, University of Bath, Claverton Down, Bath BA2 7AY, UK.
Nature
|January 24, 2003
まとめ
ヒトのアンジオテンシン変換酵素 (ACE) の最初のX線構造は,カルボキシペプチダゼAと異なることを明らかにした. この発見により,心臓血管疾患に対する新しいドメイン選択性ACE阻害剤の設計が可能になる.
科学分野:
- バイオケミストリー バイオケミストリー
- 構造生物学 構造生物学とは
- 薬理学 薬理学とは
背景:
- アンジオテンシン変換酵素 (ACE) は,アンジオテンシンIIを産生することによって心血管機能を調節する.
- ACE阻害剤は,高血圧と心不全の治療に不可欠です.
- 既存のACE阻害剤は,ヒトのACE構造に関する知識なしに設計されました.
研究 の 目的:
- 人間の丸ACEのX線構造を決定する.
- ヒトのACEの複合体を,リシノプリル阻害剤で視覚化します.
- 新種のACE阻害剤の設計に関する洞察を提供するためです.
主な方法:
- X線結晶撮影は,人間の丸ACEの構造を決定するために使用されました.
- 構造は2.0 Åの解像度で解像しました.
- リシノプリルを含む複合体を分析した.
主要な成果:
- 人間のACEの3次元構造が解明されました.
- ACEは神経リンとPyrococcus furiosusのカルボキシペプチダゼと構造的に似ているが,カルボキシペプチダゼAとは違う.
- リシノプリルとの複合体におけるACEの構造を決定した.
結論:
- 人間のACEの構造は,カルボキシペプチダゼAと異なる.
- 決定された構造は,ドメイン選択性ACE阻害剤の設計のための基礎を提供します.
- ACE阻害剤の新しい薬理学的なプロファイルは達成可能かもしれません.
関連する概念動画
01:45Kidney Structure
The kidneys are two large bean-shaped organs located in the upper abdomen. They filter the blood several times a day to remove toxins and rebalance water and electrolytes of the circulatory system via the renal veins. The kidneys receive blood directly from the heart via the renal arteries. These arteries enter the kidney at the hilum, the concave surface of the bean, where they branch and divide into smaller vessels and capillaries.
01:19Structure of Amines
The hybridized nitrogen atom in amines possesses a lone pair of electrons and is bound to three substituents with a bond angle of around 108°, which is less than the tetrahedral angle of 109.5°. However, the C–N–H bond angle is slightly larger at 112°, with a carbon–nitrogen bond length of 147 pm. This carbon–nitrogen bond length of of amines is longer than the carbon–oxygen bond of alcohols (143 pm) but shorter than alkanes’ carbon–carbon bond (154 pm). These aspects are illustrated in Figure...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...